Experimental immune cell therapy shows promise for Hard-to-Treat cancers
NCT ID NCT05729399
First seen May 03, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This early-stage trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy and interleukin-2. The main goals were to check safety and see if the treatment could shrink tumors. Only 6 people enrolled before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.